24H|Chinese ADRs Gain Ahead of US-China Trade Talks; AppLovin, Robinhood Dip Missing S&P 500 Inclusion

Tiger Newspress
06-09

Tempest Therapeutics said three of its c-suite executives transitioned to consulting agreements. The agreements have one-year terms and come as the cancer-treatment company is exploring strategic alternatives. Shares soared 39.4% in overnight trading. The European Medicines Agency (EMA) last week also has granted Orphan Drug Designation to its cancer treatment drug, amezalpat. This designation is for the treatment of hepatocellular carcinoma (HCC), the most common type of liver cancer.

Chinese ADRs gained in overnight trading. Top U.S. and Chinese officials will sit down in London on Monday for talks aimed at defusing the high-stakes trade dispute between the two superpowers that has widened in recent weeks beyond tit-for-tat tariffs to export controls over goods and components critical to global supply chains.

JD.com and WeRide rose 3%; Li Auto, NetEase, Bilibili, and Alibaba rose 2%; Pony AI, Baidu, Tencent Music, XPeng, PDD Holdings, and Trip.com rose 1%.

S&P Dow Jones Indices made no changes to the S&P 500 index on Friday, snubbing Robinhood and AppLovin. Analysts had pegged Robinhood stock and AppLovin as among the most likely additions. Carvana, Interactive Brokers and Vertiv also were cited as possible entrants.

AppLovin and Robinhood both dropped more than 5% in overnight traing, while Interactive Brokers fell 2.3%, Carvana dipped 0.8%.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10